efficacy & safety of patritumab deruxtecan for egfr nsclc - 2022 program: targeted therapies forum
Published 1 year ago • 133 plays • Length 5:23Download video MP4
Download video MP3
Similar videos
-
2:49
treatments for ret nsclc: selpercatinib vs. pralsetinib - 2022 program: targeted therapies forum
-
4:55
evolution of therapy in lung cancer - 2022 program: targeted therapies forum
-
6:14
amivantamab and lazertinib in patients with egfr nsclc - 2022 program: targeted therapies forum
-
6:40:28
full video ondemand -targeted therapies patient forum 2022 - for those living with lung cancer
-
9:28
asco 2021 lung: amivantamab lazertinib in egfr, patritumab deruxtecan in egfr acquired resistance
-
4:40
ntrk nsclc: treatment options and side effects - targeted therapies in lung cancer 2023
-
4:08
what if osimertinib stops working? - 2022 program: targeted therapies forum
-
4:51
targeted therapy side effects - lcvl 2024
-
6:52
safety and toxicity of selpercatinib versus pralsetinib - targeted therapies in lung cancer 2023
-
6:06
the adaura trial: the effect on egfr treatment - targeted therapies in lung cancer 2023
-
5:30:11
full event mainstage 2023 targeted therapies in lung cancer patient forum on-demand
-
21:33
optimal ngs platforms, how to interpret - grace targeted therapies in lung cancer patient forum 2021
-
4:42
grace targeted therapies in lung cancer 2021 - anxiety burden: wait for results, beginning treatment
-
8:49
grace targeted therapies lung cancer 2021 - a role for chemo io in patients with egfr mutations?
-
4:02
egfr resisters: an advocacy group - targeted therapies in lung cancer 2023
-
2:37
q&a: what are the platform options for sbrt? - targeted therapies in lung cancer 2023